About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

High-dose Stereotactic Body Radiotherapy Benefits Patients With Lung Tumors

by Colleen Fleiss on April 9, 2019 at 5:09 AM
Font : A-A+

High-dose Stereotactic Body Radiotherapy Benefits Patients With Lung Tumors

High-dose stereotactic body radiotherapy (SBRT) was found to be well tolerated by patients with centrally located lung tumors, found clinical trial study. However, this well-tolerated radiation treatment was not previously tested in centrally located NSCLC due to the fact that patients with centrally located lung tumors demonstrate a higher risk for toxicity if treated with high SBRT doses.

The NRG Oncology clinical study NRG-RTOG 0813 was designed to find the maximum tolerated dose (MTD) of SBRT for centrally located NSCLC in medically inoperable patients. The seamless Phase I/II study examined a 5 fraction, dose escalating schedule of SBRT that ranged from 10 to 12 Gy/fraction delivered over 1.5 to 2 weeks in 120 accrued patients from the United States and Canada. Results of this study are published in the Journal of Clinical Oncology.

Advertisement


The MTD was the highest dose level allowed by the protocol, 12.0 Gy per fraction in 5 fractions, and was associated with a 7.2% dose-limiting toxicity (DLT), defined as any treatment-related grade 3 or worse from a list of predefined toxicity types which occurred within the first year. The DLT rate of 7.2% is significantly below the protocol-specified target rate of 20%. Treatment was also associated with high rates of tumor control.

"The patients who enrolled into NRG-RTOG 0813 were medically inoperable with early stage lung cancer, mostly elderly and with co-morbidities. The two-year overall survival rates for patients at the two highest doses were 70% which is comparable to patients with peripheral early stage tumors that were treated by SBRT," stated Andrea Bezjak, MD, of the Princess Margaret Cancer Center and the lead author of NRG-RTOG 0813.
Advertisement

Two-year rates for the 71 evaluable patients in the 11.5Gy/fr and 12.0Gy/fr cohorts were: local control 89.4% (90% CI:81.6-97.4), 87.9% (90% CI :78.8-97.0); overall survival 67.9% (95%:50.4-80.3), 72.7% (95%:54.1-84.8); progression-free survival 52.2% (95%:35.3-66.6), 54.5% (95%:36.3-69.6).

"This trial demonstrated our ability to provide local control and potential for cure in patients with centrally located, node-negative tumors in multiple institutions, while maintaining plan qualities, achieving good patient outcomes, and only allowing modest rates of toxicity," added Dr. Bezjak.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Clinical Trials News

 Nanorobots: A Revolutionary Tool in Targeting Fungal Infections
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
 Gene Therapy Using Adeno Virus Reverses Age-Related Hearing Loss
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
Stickers Promise a Painless Mode of Measles Vaccine Delivery
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
 New Wearable Ultrasound Device Monitors Deep-Tissues in Moving Subjects
Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.
Exploring the Benefits of a Chemotherapy Regimen Following Pancreatic Cancer Surgery
Combination of chemotherapy drugs was found to show promising results in patients with pancreatic cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

High-dose Stereotactic Body Radiotherapy Benefits Patients With Lung Tumors Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests